39.59 USD
+0.32 (+0.81%)
39.5 USD
-0.09 (-0.23%)
Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 191 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make HRMY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year HRMY was profitable.
In the past year HRMY had a positive cash flow from operations.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HRMY (15.37%) is better than 95.29% of its industry peers.
HRMY has a Return On Equity of 22.23%. This is amongst the best in the industry. HRMY outperforms 92.67% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.20%, HRMY belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HRMY is significantly above the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
Looking at the Profit Margin, with a value of 22.48%, HRMY belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
HRMY's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 27.32%, HRMY belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
In the last couple of years the Operating Margin of HRMY has declined.
The Gross Margin of HRMY (77.70%) is better than 83.25% of its industry peers.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for HRMY has been increased compared to 1 year ago.
HRMY has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HRMY has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.74 indicates that HRMY is not in any danger for bankruptcy at the moment.
HRMY has a Altman-Z score of 5.74. This is in the better half of the industry: HRMY outperforms 77.49% of its industry peers.
HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
HRMY's Debt to FCF ratio of 0.57 is amongst the best of the industry. HRMY outperforms 96.86% of its industry peers.
HRMY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.18, HRMY perfoms like the industry average, outperforming 46.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.74 |
ROIC/WACC1.85
WACC9.3%
2.3 Liquidity
HRMY has a Current Ratio of 3.75. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a Current ratio (3.75) which is comparable to the rest of the industry.
HRMY has a Quick Ratio of 3.72. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a Quick ratio (3.72) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
The Earnings Per Share has been growing by 44.61% on average over the past years. This is a very strong growth
The Revenue has grown by 21.13% in the past year. This is a very strong growth!
Measured over the past years, HRMY shows a very strong growth in Revenue. The Revenue has been growing by 160.13% on average per year.
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
Based on estimates for the next years, HRMY will show a very strong growth in Earnings Per Share. The EPS will grow by 35.10% on average per year.
HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.64% yearly.
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.64%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 12.45, which indicates a correct valuation of HRMY.
Based on the Price/Earnings ratio, HRMY is valued cheaply inside the industry as 88.48% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of HRMY to the average of the S&P500 Index (26.76), we can say HRMY is valued rather cheaply.
The Price/Forward Earnings ratio is 9.37, which indicates a very decent valuation of HRMY.
HRMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 89.53% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.96. HRMY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.45 | ||
| Fwd PE | 9.37 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 93.72% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.68 | ||
| EV/EBITDA | 7.02 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 25.00% in the coming years.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
39.59
+0.32 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners85.21%
Inst Owner Change-7.63%
Ins Owners1.64%
Ins Owner Change-61.71%
Market Cap2.28B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target47.11 (18.99%)
Short Float %8.77%
Short Ratio4.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)4.96%
PT rev (3m)-8.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.88%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)1.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)2.01%
Revenue NY rev (3m)2.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.45 | ||
| Fwd PE | 9.37 | ||
| P/S | 2.76 | ||
| P/FCF | 7.68 | ||
| P/OCF | 7.66 | ||
| P/B | 2.73 | ||
| P/tB | 3.08 | ||
| EV/EBITDA | 7.02 |
EPS(TTM)3.18
EY8.03%
EPS(NY)4.23
Fwd EY10.67%
FCF(TTM)5.15
FCFY13.02%
OCF(TTM)5.17
OCFY13.05%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.42
PEG (5Y)N/A
Graham Number32.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.74 |
F-Score6
WACC9.3%
ROIC/WACC1.85
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.64%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.1%
EBIT Next 3Y27.64%
EBIT Next 5Y22.34%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
Can you provide the valuation status for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What is the valuation of HARMONY BIOSCIENCES HOLDINGS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 12.45 and the Price/Book (PB) ratio is 2.73.